Additional file 1: Figure S1. of MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada
Between-centre variability of optimal, under and suboptimal uses of MgSO4 among the 11 participating centres. Figure S2. Trend of antenatal corticosteroid administration over time among women with underuse of MgSO4 as a proxy for non-precipitous deliveries. Figure S3. Variability of MgSO4 use for fetal neuroprotection among MAG-CP centres (represented by the blue triangles) and non-MAG-CP centres (represented by the green circles). Table S1. MAG-CP (MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy), CPN (Canadian Perinatal Network) and CNN (Canadian Neonatal Network) collaborative groups. Table S2. Definitions of conditions and variables as used in the Canadian Perinatal Network (CPN). Table S3. Geographic regions of participating centres in the Canadian Perinatal Network (CPN). Table S4. Absolute utilisation rates of MgSO4 for fetal NP by study time period (from August 01/05 to September 30/15). Table S5. Segmented regression analysis of the nine centres that contributed data to both pre-MAG-CP and MAG-CP eras. Table S6. Sensitivity analyses of overall utilisation rates of MgSO4 using data from the nine centres that contributed data to both pre-MAG-CP and MAG-CP eras. Table S7. Determinants of engagement of participating sites in MAG-CP. Table S8. Components of engagement and relation to optimal use. Table S9. Antenatal MgSO4 use at GA 24–31+6 weeks by indication, from Jan 1/11 to Sep 30/15. (DOCX 281 kb
